Effects of High-Dose Octreotide LAR on Glucose Metabolism in Patients With Acromegaly Inadequately Controlled by Conventional Somatostatin Analogue Therapy
| Autor: | Annamaria Colao, Laura De Marinis, Fausto Bogazzi, Maurizio Spinello, Francesco Minuto, Giovanna Bugari, Andrea Giustina, Teresa Porcelli, Renato Cozzi, Salvatore Cannavò, Gherardo Mazziotti, Silvia Grottoli, Ettore C. degli Uberti, M. Montini |
|---|---|
| Přispěvatelé: | G., Mazziotti, T., Porcelli, F., Bogazzi, G., Bugari, S., Cannavò, Colao, Annamaria, R., Cozzi, L., De Marini, E., Degli Uberti, S., Grottoli, F., Minuto, M., Montini, M., Spinello, A., A. G. i. u. s. t. i. n., Mazziotti, G, Porcelli, T, Bogazzi, F, Bugari, G, Cannavò, S, Colao, A, Cozzi, R, De Marinis, L, degli Uberti, E, Grottoli, S, Minuto, F, Montini, M, Spinello, M, Giustina, Andrea |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Endocrinology
Diabetes and Metabolism Octreotide Diabete Impaired glucose tolerance Endocrinology dose response Medicine Analoghi della Somatostatina hemoglobin A1c clinical article Human Growth Hormone adult article clinical trial General Medicine Middle Aged somatostatin analogs GH IGF-I Ipofisi growth hormone octreotide somatomedin C acromegaly aged conservative treatment controlled clinical trial controlled study diet restriction disease exacerbation female glucose metabolism human impaired glucose tolerance male priority journal randomized controlled trial treatment duration treatment outcome Somatostatin diabetes mellitus IGF-1 medicine.drug medicine.medical_specialty Antineoplastic Agents Hormonal Carbohydrate metabolism Acromegalia Internal medicine Diabetes mellitus Acromegaly Humans acromegaly Glycated Hemoglobin therapy glucose business.industry Settore MED/13 - ENDOCRINOLOGIA Metabolism Impaired fasting glucose medicine.disease somatomedin C Glucose business |
| Popis: | ObjectiveIn this study, the effect of high-dose octreotide LAR on glucose metabolism in patients with acromegaly was investigated.DesignA post-hoc analysis of a clinical trial enrolling 26 patients with acromegaly not controlled by standard maximal somatostatin analog (SSAs) dose and randomized to receive high-dose (60 mg/28 days) or high-frequency (30 mg/21 days) octreotide i.m. injection (octreotide LAR) for 6 months.MethodsGlucose metabolic status was defined as worsened when a progression from normoglycemia to impaired fasting glucose (IFG) or from IFG to diabetes occurred or when an increase of HbAlc by at least 0.5% was demonstrated. An improvement of glucose metabolism was defined in the presence of a regression from IFG to normoglycemia and/or when HbAlc decreased by at least 0.5%.ResultsGlucose metabolic status remained unchanged in a majority of patients (16/26 patients, 65.3%), worsened in six patients, and improved in four patients. Pre-existing metabolic status did not predict worsening of glucose metabolism, which, conversely, was significantly related to persistent biochemical activity of the disease. In fact, patients with worsened glucose metabolism exhibited a less frequent decrease in serum GH and IGF1 levels, compared with patients with improved or unchanged glucose metabolism (2/6 vs 18/20; P=0.01).ConclusionAn increase in octreotide LAR dose or frequency did not impact on glucose metabolism in most patients. Worsening of glucose metabolic status occurred in close relation with persistently uncontrolled acromegaly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|